Prospective, Multicenter, Phase II Study on Reducing the Dosage of Idarubicin and FLAG for Patients Younger than 65 Years with Resistant Acute Myeloid Leukemia: A Comparison with a Higher Dosage Trial | Citedby Results | Acta Haematologica | Karger Publishers

Skip to Main Content

Skip Nav Destination

Prospective, Multicenter, Phase II Study on Reducing the Dosage of Idarubicin and FLAG for Patients Younger than 65 Years with Resistant Acute Myeloid Leukemia: A Comparison with a Higher Dosage Trial

Acta Haematol (2014) 132 (1): 87–96.

This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.

Real-world results of venetoclax combined with hypomethylating agents in young adults with relapsed/refractory acute myeloid leukemia

Xuezhu Xu
Rui Liu
Aili He
Fangxia Wang

Hematology (2023) 28 (1)

FLAG salvage therapy combined with idarubicin in relapsed/refractory acute myeloid leukemia

Jonas Westhus
Richard Noppeney
Ulrich Dührsen
Maher Hanoun

Leukemia & Lymphoma (2019) 60 (4): 1014.

Salvage regimens using conventional chemotherapy agents for relapsed/refractory adult AML patients: a systematic literature review

Juan Eduardo Megías-Vericat
David Martínez-Cuadrón
Miguel Ángel Sanz
Pau Montesinos

Annals of Hematology (2018) 97 (7): 1115.

A prospective, multicenter phase II study of continuous infusion of FLAG for patients older than 60 yr with resistant acute myeloid leukemia: a comparison with intensive younger patients’ trial

Hawk Kim
Je‐Hwan Lee
Young‐Don Joo
Sung Hwa Bae
Jung‐Hee Lee
Dae‐Young Kim
Won‐Sik Lee
Hun‐Mo Ryoo
Jae‐Cheol Jo
Yunsuk Choi
Kyoo‐Hyung Lee

European Journal of Haematology (2016) 96 (2): 188.